These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 26195437)

  • 1. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
    Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
    Ignatov T; Poehlmann A; Ignatov A; Schinlauer A; Costa SD; Roessner A; Kalinski T; Bischoff J
    Breast Cancer Res Treat; 2013 Sep; 141(2):205-12. PubMed ID: 24026861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    Tian T; Shan L; Yang W; Zhou X; Shui R
    Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
    Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
    J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
    Gupta S; Jaworska-Bieniek K; Narod SA; Lubinski J; Wojdacz TK; Jakubowska A
    Breast Cancer Res Treat; 2014 Dec; 148(3):615-22. PubMed ID: 25376744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
    Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
    Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
    Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
    BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers.
    Boukerroucha M; Josse C; ElGuendi S; Boujemla B; Frères P; Marée R; Wenric S; Segers K; Collignon J; Jerusalem G; Bours V
    BMC Cancer; 2015 Oct; 15():755. PubMed ID: 26490435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
    Arif T; Anwar N
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2395-2401. PubMed ID: 32856871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
    Prajzendanc K; Domagała P; Hybiak J; Ryś J; Huzarski T; Szwiec M; Tomiczek-Szwiec J; Redelbach W; Sejda A; Gronwald J; Kluz T; Wiśniowski R; Cybulski C; Łukomska A; Białkowska K; Sukiennicki G; Kulczycka K; Narod SA; Wojdacz TK; Lubiński J; Jakubowska A
    Int J Cancer; 2020 Mar; 146(5):1293-1298. PubMed ID: 31469414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
    Morizono A; Tanabe M; Ikemura M; Sasaki T; Ushiku T; Seto Y
    J Hum Genet; 2021 Aug; 66(8):785-793. PubMed ID: 33640902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
    Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
    Wei M; Grushko TA; Dignam J; Hagos F; Nanda R; Sveen L; Xu J; Fackenthal J; Tretiakova M; Das S; Olopade OI
    Cancer Res; 2005 Dec; 65(23):10692-9. PubMed ID: 16322213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.
    Daniels SL; Burghel GJ; Chambers P; Al-Baba S; Connley DD; Brock IW; Cramp HE; Dotsenko O; Wilks O; Wyld L; Cross SS; Cox A
    PLoS One; 2016; 11(7):e0160174. PubMed ID: 27463681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological significance of BRCA1 promoter hypermethylation in Thai breast cancer patients.
    Saelee P; Chaiwerawattana A; Ogawa K; Cho YM; Tiwawech D; Suktangman V
    Asian Pac J Cancer Prev; 2014; 15(24):10585-9. PubMed ID: 25605143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer.
    Lønning PE; Nikolaienko O; Pan K; Kurian AW; Eikesdal HP; Pettinger M; Anderson GL; Prentice RL; Chlebowski RT; Knappskog S
    JAMA Oncol; 2022 Nov; 8(11):1579-1587. PubMed ID: 36074460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients.
    Ben Gacem R; Hachana M; Ziadi S; Amara K; Ksia F; Mokni M; Trimeche M
    Cancer Epidemiol; 2012 Apr; 36(2):190-7. PubMed ID: 21978880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.